Federated Hermes’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-31,714
| Closed | -$2.32M | – | 2090 |
|
|
2024
Q1 | $2.32M | Sell |
31,714
-7,250
| -19% | -$535K | 0.01% | 893 |
|
|
2023
Q4 | $2.78M | Sell |
38,964
-10,060
| -21% | -$594K | 0.01% | 864 |
|
|
2023
Q3 | $2.94M | Sell |
49,024
-245
| -0.5% | -$16.1K | 0.01% | 823 |
|
|
2023
Q2 | $3.55M | Sell |
49,269
-1,959
| -4% | -$147K | 0.01% | 789 |
|
|
2023
Q1 | $3.77M | Buy |
51,228
+23,661
| +86% | +$1.68M | 0.01% | 775 |
|
|
2022
Q4 | $1.84M | Buy |
27,567
+27,556
| +250,509% | +$1.79M | 0.01% | 937 |
|
|
2022
Q3 | $1K | Hold |
11
| – | – | ﹤0.01% | 2054 |
|
|
2022
Q2 | $1K | Sell |
11
-6,836
| -100% | -$622K | ﹤0.01% | 2052 |
|
|
2022
Q1 | $770K | Sell |
6,847
-2,346
| -26% | -$273K | ﹤0.01% | 1334 |
|
|
2021
Q4 | $1.42M | Sell |
9,193
-3
| -0% | -$444 | ﹤0.01% | 1152 |
|
|
2021
Q3 | $1.28M | Sell |
9,196
-56,181
| -86% | -$6.97M | ﹤0.01% | 1191 |
|
|
2021
Q2 | $8.58M | Buy |
65,377
+52,377
| +403% | +$6.98M | 0.02% | 709 |
|
|
2021
Q1 | $1.98M | Sell |
13,000
-23,173
| -64% | -$3.51M | ﹤0.01% | 1109 |
|
|
2020
Q4 | $3.6M | Buy |
36,173
+12,789
| +55% | +$1.17M | 0.01% | 899 |
|
|
2020
Q3 | $2.23M | Buy |
23,384
+21,216
| +979% | +$2.32M | 0.01% | 950 |
|
|
2020
Q2 | $242K | Sell |
2,168
-9
| -0.4% | -$915 | ﹤0.01% | 1607 |
|
|
2020
Q1 | $158K | Sell |
2,177
-470
| -18% | -$42.7K | ﹤0.01% | 1601 |
|
|
2019
Q4 | $276K | Sell |
2,647
-646
| -20% | -$69.2K | ﹤0.01% | 1550 |
|
|
2019
Q3 | $328K | Sell |
3,293
-590
| -15% | -$59.4K | ﹤0.01% | 1507 |
|
|
2019
Q2 | $443K | Sell |
3,883
-3,530
| -48% | -$417K | ﹤0.01% | 1453 |
|
|
2019
Q1 | $932K | Buy |
7,413
+216
| +3% | +$26.2K | ﹤0.01% | 1333 |
|
|
2018
Q4 | $977K | Sell |
7,197
-21,226
| -75% | -$3.63M | ﹤0.01% | 1294 |
|
|
2018
Q3 | $7.8M | Hold |
28,423
| – | – | 0.02% | 665 |
|
|
2018
Q2 | $13.6M | Buy |
65,639
+48,953
| +293% | +$8.76M | 0.04% | 351 |
|
|
2018
Q1 | $2.76M | Sell |
16,686
-5,901
| -26% | -$935K | 0.01% | 836 |
|
|
2017
Q4 | $3.09M | Buy |
22,587
+8,310
| +58% | +$1.15M | 0.01% | 773 |
|
|
2017
Q3 | $1.94M | Buy |
+14,277
| New | +$1.81M | 0.01% | 929 |
|
|
2016
Q3 | – | Sell |
-4,634
| Closed | -$553K | – | 2143 |
|
|
2016
Q2 | $553K | Buy |
4,634
+4,603
| +14,848% | +$548K | ﹤0.01% | 1253 |
|
|
2016
Q1 | $3K | Buy |
+31
| New | +$3.02K | ﹤0.01% | 1939 |
|
|
2015
Q4 | – | Sell |
-1,455
| Closed | -$125K | – | 2123 |
|
|
2015
Q3 | $125K | Buy |
1,455
+711
| +96% | +$69.2K | ﹤0.01% | 1553 |
|
|
2015
Q2 | $75K | Buy |
+744
| New | +$65.1K | ﹤0.01% | 1612 |
|
|
2015
Q1 | – | Sell |
-56
| Closed | -$3K | – | 2043 |
|
|
2014
Q4 | $3K | Sell |
56
-25,523
| -100% | -$1.33M | ﹤0.01% | 1892 |
|
|
2014
Q3 | $1.2M | Buy |
25,579
+4,509
| +21% | +$240K | ﹤0.01% | 1148 |
|
|
2014
Q2 | $1.31M | Buy |
21,070
+9,756
| +86% | +$635K | ﹤0.01% | 1104 |
|
|
2014
Q1 | $761K | Buy |
11,314
+10,038
| +787% | +$671K | ﹤0.01% | 1237 |
|
|
2013
Q4 | $67K | Sell |
1,276
-848
| -40% | -$44.3K | ﹤0.01% | 1630 |
|
|
2013
Q3 | $92K | Sell |
2,124
-1,422
| -40% | -$64.1K | ﹤0.01% | 1574 |
|
|
2013
Q2 | $133K | Hold |
3,546
| – | – | ﹤0.01% | 1488 |
|
Other funds holding LGND
Federated Hermes's LGND Position: Q2 2024 in Review
Federated Hermes sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 31,714 shares — an estimated $2.32M sold.
Federated Hermes first reported a position in LGND in Q2 2013 and held it in 38 quarters. The position peaked at $13.6M in Q2 2018. 235 funds tracked by Wall St. Rank hold LGND as of Q2 2024.
- Federated Hermes reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- Federated Hermes sold 31,714 Ligand Pharmaceuticals shares in Q2 2024, an estimated $2.32M.
- Federated Hermes first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 38 quarters.
- Federated Hermes's Ligand Pharmaceuticals position peaked at $13.6M in Q2 2018.
- 235 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.